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Can Achalasia Subtyping by High-Resolution 
Manometry Predict the Therapeutic Outcome 
of Pneumatic Balloon Dilatation?
TO THE EDITOR: I read with great interest the paper entitled 
“Achalasia cardia subtyping by high-resolution manometry pre-
dicts the therapeutic outcome of pneumatic balloon dilatation” by 
Pratap et al,
1 which was published in January 2011 issue of 
Journal of Neurogastroenterology and Motility. Achalasia is the best 
known primary esophageal motility disorder characterized by ab-
sent peristalsis of esophageal body and failure of relaxation of 
lower esophageal sphincter (LES). The aim of therapy is to re-
duce LES pressure and allow esophageal emptying. This can be 
done well by pneumatic balloon dilatation (PD), botulinum toxin 
injection or surgical myotomy. For many gastroenterologist, PD 
is considered as first-line therapy. However, the success rate of 
PD is reported to be between 35% and 85%.
2-4 This marked dif-
ference of results hampers the use of PD as primary therapy for 
achalasia. Therefore, it is important to know PD outcomes and 
possible predictive response factors that can help select the group 
of patients to benefit from PD. 
   In January issue of the Journal, Pratap et al
1 classified the 3 
subtypes of achalasia based on high-resolution manometry (HRM) 
findings and compared the clinical characteristics, manometric 
variables and outcomes of PD within the subtypes of achalasia. 
What the authors found was that the type II achalasia showed the 
better response to PD compared to other subtypes. However, this 
study failed to find a statistically significant correlation between 
age, sex or duration of symptoms and the therapeutic outcomes. 
They concluded that the subtyping of achalasia by HRM may al-
low the clinician to direct therapy and predict outcomes. 
   However, there are several limitations regarding this study. 
First, the previous identified risk factors for symptom recurrence 
after PD are mainly young age, male, a short history of symptoms 
before therapy, low pre-therapy LES pressure and post- therapy 
LES pressure above 10 mmHg.
5-8 But age, sex and duration of 
symptoms did not affect the therapeutic outcome in this study. 
There were no explanations for this discrepancy in discussion. 
Second, the length of follow-up and the evaluation time point of 
primary response rate were too short. Also, the definition of re-
currence and success was not described in detail. These points 
may affect the success rate of PD. Third, as the authors de-
scribed, one of the strengths of this study is to classify the sub-
types of achalasia by HRM and compare the therapeutic out-
comes among the subtypes. This study was performed with small 
groups of patients (especially just 3 type III patients). Previously, 
advanced age and female gender were associated with favorable 
therapeutic outcomes.
5-8 Although statistically not significant, 
type II group of patients were older than other types and type I 
group included more male patients than female. In smaller stud-
ies, these minimal bias may partly affect the results which is the 
major concern of this study. Therefore, the conclusion that 
HRM could predict the response to PD is not evident.
　Further studies with large cases are needed to solve the limi-
tations of present study and to identify predicting factors for out-
come of PD in patients with achalasia.
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